Viridian says elegrobart meets primary goal in thyroid eye disease trial

March 30, 2026 7:02 AM

Viridian Therapeutics Inc. (NASDAQ: VRDN) reported that its experimental drug elegrobart met the primary endpoint in a phase 3 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found